Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar 1;22(127):53-7.
doi: 10.1183/09059180.00008312.

Stratified medicine: drugs meet genetics

Affiliations
Review

Stratified medicine: drugs meet genetics

Ian P Hall. Eur Respir Rev. .

Abstract

It is well recognised that genetic factors play a major role in the development of respiratory diseases such as asthma and chronic obstructive pulmonary disease. However, whilst extensive data exist on diseases caused primarily by single gene defects, such as α1-antitrypsin deficiency, the genetic factors responsible for the development of complex disease are only now being defined. Once the gene(s) responsible for the heritable element of disease risk are known, the next step is to identify the mechanisms underlying the pathophysiological effects of the causal mutations in these genes. This process can be time consuming, but allows a full understanding of the mechanisms underlying disease development to be obtained. This knowledge can then potentially be used to stratify patient groups within (or even across) disease boundaries and then to target therapy more effectively.

PubMed Disclaimer

Conflict of interest statement

Statement of Interest

I.P. Hall received a speaker’s fee for participating in the sponsored symposium at the 2012 European Respiratory Society Congress. Work in I.P. Hall’s laboratory relevant to the content of this review has been funded by the Medical Research Council, Asthma UK and Pfizer.

References

    1. Fukuoka M, Yano S, Giaccone G, et al. . Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21: 2237–2246. - PubMed
    1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–132. - PubMed
    1. Keedy VL, Temin S, Somerfield MR, et al. . American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011; 20: 2121–2127. - PubMed
    1. Soda M, Choi YL, Enomoto M, et al. . Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561–566. - PubMed
    1. Kwak EL, Bang YJ, Camidge DR, et al. . Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693–1703. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources